DiaMedica Therapeutics (DMAC) Capital Expenditures (2018 - 2026)
DiaMedica Therapeutics (DMAC) posted quarterly Capital Expenditures of $8000.0 for Q1 2026, down 33.33% year-over-year from $12000.0 in Q1 2025, and up 33.33% quarter-over-quarter from $6000.0 in Q4 2025.
DiaMedica Therapeutics (DMAC) Capital Expenditures (2018 - 2026) Analysis & Trends
DiaMedica Therapeutics' Capital Expenditures history runs 9 years deep, the most recent figure standing at $8000.0 for Q1 2026.
- In Q1 2026, Capital Expenditures fell 33.33% year-over-year to $8000.0; the TTM figure through Mar 2026 stood at $36000.0 (up 28.57% YoY), while the FY2025 annual figure was $40000.0, up 60.0% from the prior year.
- Capital Expenditures for Q1 2026 stood at $8000.0, up from $6000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $43000.0 in Q3 2022, with the low at $3000.0 in Q4 2023.
- The 5-year median for Capital Expenditures is $8000.0 (2026), against an average of $11866.7.
- The sharpest annual moves came in 2022 and 2023: Capital Expenditures surged 2050.0% in 2022, then plunged 90.62% in 2023.
- DiaMedica Therapeutics' Capital Expenditures stood at $32000.0 in 2022, then slumped by 90.62% to $3000.0 in 2023, then soared by 133.33% to $7000.0 in 2024, then decreased by 14.29% to $6000.0 in 2025, then jumped by 33.33% to $8000.0 in 2026.
- Business Quant data shows DMAC's Capital Expenditures at $8000.0 in Q1 2026, $6000.0 in Q4 2025, and $16000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | DiaMedica Therapeutics | 360.22 Mn | 360.22 Mn | - | 3,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3,000.00 |
| Jun 30, 2026 | 3,000.00 |
| Mar 31, 2026 | 8,000.00 |
| Mar 31, 2026 | 8,000.00 |
| Dec 31, 2025 | 6,000.00 |
| Dec 31, 2025 | 6,000.00 |
| Sep 30, 2025 | 16,000.00 |
| Sep 30, 2025 | 16,000.00 |
| Jun 30, 2025 | 6,000.00 |
| Jun 30, 2025 | 6,000.00 |
| Mar 31, 2025 | 12,000.00 |
| Mar 31, 2025 | 12,000.00 |
| Dec 31, 2024 | 7,000.00 |
| Dec 31, 2024 | 7,000.00 |
| Sep 30, 2024 | 9,000.00 |
| Sep 30, 2024 | 9,000.00 |
| Mar 31, 2024 | 9,000.00 |
| Mar 31, 2024 | 9,000.00 |
| Dec 31, 2023 | 3,000.00 |
| Dec 31, 2023 | 3,000.00 |